Celularity’s Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific
Celularity (CELU) announced that its strategic partner, Genting Berhad, has broken ground on Fontaine Vitale, a state-of-the-art stem cell and regenerative medicine facility in Bali, Indonesia. The facility will use Celularity's placenta-derived stem cells manufactured in their US facility. Operations are expected to start by late 2026. The Asia Pacific stem cell market is valued at $3.0 billion (2024) with projected growth to $7.2 billion by 2030 at a 16.4% CAGR. Future plans include initiating onsite manufacturing operations under Celularity's technical supervision.
Celularity (CELU) ha annunciato che il suo partner strategico, Genting Berhad, ha iniziato i lavori per Fontaine Vitale, una struttura all'avanguardia per cellule staminali e medicina rigenerativa a Bali, Indonesia. La struttura utilizzerà le cellule staminali derivate dalla placenta di Celularity prodotte nel loro stabilimento negli Stati Uniti. Le operazioni sono previste per iniziare entro la fine del 2026. Il mercato delle cellule staminali dell'Asia-Pacifico è valutato 3,0 miliardi di dollari (2024) con una crescita prevista a 7,2 miliardi di dollari entro il 2030 a un CAGR del 16,4%. I piani futuri includono l'avvio delle operazioni di produzione in loco sotto la supervisione tecnica di Celularity.
Celularity (CELU) anunció que su socio estratégico, Genting Berhad, ha iniciado la construcción de Fontaine Vitale, una instalación de vanguardia para células madre y medicina regenerativa en Bali, Indonesia. La instalación utilizará células madre derivadas de la placenta de Celularity fabricadas en su instalación en EE. UU. Se espera que las operaciones comiencen a finales de 2026. El mercado de células madre de Asia-Pacífico está valorado en 3.0 mil millones de dólares (2024) con un crecimiento proyectado a 7.2 mil millones de dólares para 2030 a una TACC del 16.4%. Los planes futuros incluyen iniciar operaciones de fabricación in situ bajo la supervisión técnica de Celularity.
셀룰러리티(CELU)는 전략적 파트너인 겐팅 베르하드가 인도네시아 발리에 최첨단 줄기세포 및 재생 의학 시설인 폰테인 비탈의 기공식이 진행되었다고 발표했습니다. 이 시설은 미국 시설에서 생산된 셀룰러리티의 태반 유래 줄기세포를 사용할 예정입니다. 운영은 2026년 말까지 시작될 것으로 예상됩니다. 아시아 태평양의 줄기세포 시장은 30억 달러 (2024년)로 평가되며, 2030년까지 72억 달러로 성장할 것으로 예상되며, 연평균 16.4%의 성장률을 보일 것으로 예상됩니다. 향후 계획에는 셀룰러리티의 기술 감독 아래 현장 제조 작업을 시작하는 것이 포함됩니다.
Celularity (CELU) a annoncé que son partenaire stratégique, Genting Berhad, a lancé la construction de Fontaine Vitale, une installation de pointe pour cellules souches et médecine régénérative à Bali, en Indonésie. L'installation utilisera les cellules souches dérivées du placenta de Celularity fabriquées dans son usine aux États-Unis. Les opérations devraient commencer d'ici la fin de 2026. Le marché des cellules souches dans la région Asie-Pacifique est évalué à 3,0 milliards de dollars (2024) avec une croissance projetée à 7,2 milliards de dollars d'ici 2030 à un TAC de 16,4 %. Les futurs plans incluent le démarrage des opérations de fabrication sur site sous la supervision technique de Celularity.
Celularity (CELU) hat angekündigt, dass sein strategischer Partner, Genting Berhad, mit dem Bau von Fontaine Vitale, einer hochmodernen Einrichtung für Stammzellen und regenerative Medizin in Bali, Indonesien, begonnen hat. Die Einrichtung wird stammzellen aus der Plazenta von Celularity verwenden, die in ihrer US-Einrichtung hergestellt werden. Der Betrieb wird voraussichtlich Ende 2026 beginnen. Der Markt für Stammzellen im asiatisch-pazifischen Raum wird auf 3,0 Milliarden USD (2024) geschätzt, mit einem prognostizierten Wachstum auf 7,2 Milliarden USD bis 2030 bei einer CAGR von 16,4%. Zukünftige Pläne umfassen den Beginn der Herstellungsoperationen vor Ort unter der technischen Aufsicht von Celularity.
- Strategic expansion into Asia Pacific's growing stem cell market worth $3.0B
- Access to new revenue stream through product supply to Fontaine Vitale facility
- Future opportunity for technology transfer and manufacturing expansion in Asia
- Commercial operations won't begin until late 2026, indicating delayed revenue impact
- Significant capital investment and resources required for future manufacturing setup
Insights
The groundbreaking of Fontaine Vitale represents a significant market expansion opportunity for Celularity into the rapidly growing Asia Pacific stem cell market, valued at
The collaboration provides multiple revenue streams: initial product supply from US facilities, potential technology transfer fees for future local manufacturing and ongoing royalties. The Special Economic Zone location offers tax advantages and regulatory benefits that could accelerate market penetration. However, investors should note that commercial operations won't begin until late 2026, requiring patience for revenue realization.
The strategic value of this partnership extends beyond immediate commercial potential. Bali's emergence as a medical tourism hub, combined with Celularity's placenta-derived stem cell expertise, creates a unique positioning in the regenerative medicine landscape. The facility will serve both local and international patients, potentially validating Celularity's therapeutic approach in diverse populations.
The planned transition to local manufacturing under Celularity's supervision demonstrates a thoughtful approach to market development while maintaining quality control. This model could serve as a template for future geographic expansion while protecting intellectual property and maintaining manufacturing standards.
- Celularity is collaborating with its strategic partner, Genting Berhad, to bring Celularity placenta-derived allogeneic stem cell therapeutics to the Asia Pacific region
- Genting Berhad announced groundbreaking on a new, state-of-the-art wellness and health center in Bali, Indonesia, that will utilize Celularity products
- Strategic partnership positions Celularity to be a key supplier of innovative stem cell and regenerative medicine products for use in the Asia Pacific region
FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that its strategic partner, Genting Berhad, has broken ground on Fontaine Vitale, a state-of-the-art stem cell and regenerative medicine facility in the Sanur Special Economic Zone located in Bali, Indonesia. Fontaine Vitale will offer world-class cell therapies focused on wellness, aesthetics, and regenerative medicine to both local and international patients using placenta-derived stem cells manufactured by Celularity in its US facility, according to Genting Berhad's press release. The new center is expected to commence commercial operations towards the end of 2026.
As disclosed by Genting Berhad, Celularity will manufacture stem cells for export and use at the Sanur Special Economic Zone facility at Celularity’s 150,000sf cGMP research and manufacturing center located in Florham Park, NJ. Longer term, Genting Berhad and Celularity expect to initiate onsite manufacturing operations in the Sanur Special Economic Zone under Celularity’s technical supervision.
The Asia Pacific stem cell market is estimated at USD 3.0 billion (2024) and expected to grow at a CAGR of
Robert J. Hariri, MD, PhD, Celularity’s Founder, Chairman, and CEO, remarked, "We are honored to collaborate with Genting Berhad to bring our innovative placenta-derived allogeneic stem cell therapy to Indonesia and the Asia Pacific region. Our strategic partnership will address demand for innovative stem cell and regenerative medicine treatments at the highest standards of quality and safety. Fontaine Vitale will mark a significant step forward in making stem cell therapies and regenerative medicine more accessible to patients globally, and we are excited to contribute to Bali’s emergence as a hub for world-class medical tourism."
About Celularity
Celularity Inc. (Nasdaq: CELU) is a regenerative medicine company developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placenta-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies. For more information, visit www.celularity.com.
About Genting
Genting Berhad is principally an investment holding and management company. While the Company was incorporated in 1968 and listed in 1971, the Genting Group was founded in 1965 when its Founder, the late Tan Sri Lim Goh Tong started the journey to realise his vision of building a mountaintop resort in Malaysia. Today, the Genting Group comprises Genting Berhad and its listed companies; Genting Malaysia Berhad, Genting Plantations Berhad and Genting Singapore Limited, as well as its wholly owned unlisted subsidiaries Genting Energy Limited and Resorts World Las Vegas LLC.
Led by Tan Sri Lim Kok Thay, the Group is involved in leisure and hospitality, oil palm plantations, power generation, oil and gas, property development, life sciences and biotechnology activities, with operations spanning across the globe, including in Malaysia (the Group’s country of origin), Singapore, Indonesia, India, China, the United States of America, Bahamas, the United Kingdom and Egypt. In the core leisure and hospitality business, the Genting Group markets and offers a suite of products under a number of premier brands including Genting, Resorts World, Genting Grand, Genting Club, Crockfords and Maxims. The Genting Group has tie ups with established names such as Universal Studios, Premium Outlets, Zouk, Hard Rock Hotel, Hilton, Hyatt and other renowned international brand partners.
For more information, visit www.genting.com.
Celularity Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as well as within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “might,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. The forward-looking statements in this press release include express or implied statements regarding the market opportunity for Celularity’s products; growth in the Asia Pacific stem cell market; Celularity’s ability to export products into the Sanur Special Economic Zone or elsewhere, among others. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including but not limited to: Celularity’s liquidity situation; the volatility in Celularity’s stock price; inherent risks in biotechnological development, including with respect to the development of novel advanced biomaterials; and the regulatory approval process domestically and abroad; along with those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on July 30, 2024, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor Contact:
Carlos Ramirez
Senior Vice President, Celularity Inc.
Carlos.ramirez@celularity.com
Media Contacts:
Raquel Cona / Michaela Fawcett
KCSA Strategic Communications
rcona@kcsa.com / mfawcett@kcsa.com
FAQ
When will Celularity's (CELU) Fontaine Vitale facility in Bali begin operations?
What is the projected size of the Asia Pacific stem cell market by 2030?
Where will Celularity (CELU) manufacture stem cells for the Bali facility?
